M. Wong

发表

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.

R. Dubridge, S. Watson, P. Hevezi, 2006, Journal of experimental therapeutics & oncology.

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008, Clinical Cancer Research.

CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008 .

STAT3 mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8 + T cell memory formation and function

S. Choo, Joanne M. Smart, C. Picard, 2013 .

Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity.

F. Harding, A. Reddy, P. Hinton, 2019, Protein engineering, design & selection : PEDS.

Activating mutations in PIK3CD and murine CD4 + T cells

L. Notarangelo, S. Choo, Joanne M. Smart, 2019 .

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

R. Dubridge, S. Rhodes, V. Ramakrishnan, 2008, Investigational new drugs.

A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

R. Dubridge, D. Chao, V. Ramakrishnan, 2007, Journal of Translational Medicine.

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

S. Ybarra, R. Dubridge, D. Chao, 2010, Clinical Cancer Research.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Eric Ibsen, Richard Murray, Robert L Sutherland, 2004, Molecular cancer therapeutics.

Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer⋆

K. Gish, J. Kench, R. Sutherland, 2003, Oncogene.